Semaglutide

SALE -20%Semaglutide 10 mg research vial
PHONYX SCIENTIFIC COMPOUND REVIEW

GLP-S1

Catalogue code GLP-S1 identifies a peptide research material documented for laboratory investigation of defined receptor-signalling pathways. Compound identity is provided below for analytical reference.

Purity ≥99%Lyophilized powderGLP-1 receptor agonist

The listed format is the total vial content in the PHONYX research portfolio. It is not a weekly clinical dose.

AVAILABLE PRODUCT

Semaglutide 10 mg

View Cart
Original price was: 90,00 €.Current price is: 72,00 €.
In stock

For laboratory research only. Not for human consumption.

GLP-S1 research material

GLP-S1 is the PHONYX catalogue code for Semaglutide. The material is presented for laboratory research and analytical reference. Its scientific relevance is based on receptor-binding and signalling characteristics described in the published literature.

The information on this page concerns compound identity, molecular targets and laboratory material specifications. It does not provide administration, dosing, treatment or self-use guidance.

Catalogue codeGLP-S1
Compound identitySemaglutide
CAS No.910463-68-2
Molecular formulaC187H291N45O59
Approx. molecular mass≈4114 Da
FormLyophilized powder
Available vial content10 mg
CategoryMetabolic Research

Selective GLP-1 receptor agonism

Glucose-dependent signalling

GLP-1 receptor activation enhances insulin secretion when glucose concentrations are elevated and reduces inappropriate glucagon release.

Appetite regulation

Central and peripheral GLP-1 pathways influence satiety, food intake and reward-related responses to food.

Gastric emptying

Semaglutide can slow gastric emptying, particularly during treatment initiation, contributing to post-meal glucose and appetite effects.

Receptor profile

CompoundGLP-1RGIPRGCGR
Semaglutide✓——
Tirzepatide✓✓—
Retatrutide✓✓✓

PHONYX portfolio format

Compound identitySemaglutide
Available format10 mg
FormLyophilized powder
Purity≥99%
CategoryMetabolic Research
Storage before reconstitutionCool, dry and protected from light

Evidence behind the key claims

Frequently asked questions

How does semaglutide differ from tirzepatide?

Semaglutide selectively activates GLP-1 receptors, while tirzepatide activates both GIP and GLP-1 receptors.

Research Use Only

GLP-S1 (Semaglutide) is presented exclusively as a laboratory research material. Not for human or veterinary use, consumption or administration. The listed mg values indicate total vial content only and are not dosing instructions. Product information is provided for compound identification, analytical reference and laboratory research context.